Definium to File DT120 Drug Application to To Be Filed in 2027
Definium Therapeutics expects to file a New Drug Application for DT120 ODT in the first half of 2027 and says its cash will fund operations into 2030.
Updated on Nov. 11, 2026 in Corporate Finance

Definium Therapeutics remains on track to file a New Drug Application for DT120 ODT in the first half of 2027. The company reported $1.046848 billion in cash, cash equivalents and short-term investments as of Sept. 30.
Why it matters
DT120 ODT is being studied for generalized anxiety disorder and major depressive disorder, and the company has not yet earned revenue or brought a product to market. The stated runway into 2030 depends on its current operating plan and anticipated milestones, which could vary materially.
Definium reported $241.150 million in cash and cash equivalents and $805.698 million in short-term investments as of Sept. 30, totaling $1.046848 billion. The extraction provides no prior-period comparator, and the company warns that actual results could vary materially from its runway estimate.
The players
Definium Therapeutics
Definium Therapeutics is the company developing DT120 ODT, a lysergide D-tartrate-based candidate.
The details
Definium Therapeutics reported positive Phase 3 topline results from its Voyage and Panorama studies this quarter. The company plans to begin a Phase 3 study for post-traumatic stress disorder in 2027.
Timeline
Sept. 30: Cash and short-term investments totaled $1.046848 billion.
Nov. 9: Company announced its NDA filing timeline and runway into 2030.
This quarter: Positive Phase 3 topline results from Voyage and Panorama were reported.
First half of 2027: Planned New Drug Application filing for DT120 ODT.
2027: Planned start of a Phase 3 study for post-traumatic stress disorder.
Market Dynamics
DT120 ODT is a lysergide D-tartrate-based candidate now moving toward regulatory filing, placing Definium's runway and filing timeline within the broader pipeline of psychedelic-derived treatments being studied for anxiety and depression. The company's plan to extend the program to post-traumatic stress disorder in 2027 marks a continuation of that development strategy.
Investors tracking Definium should note that the company has no revenue yet and its cash position is reported as of Sept. 30. The runway into 2030 is a company estimate that may change as milestones are reached.
The takeaway
Biotech runway estimates depend on milestone timing, so readers should track filing and trial progress against the company's stated 2027 targets. Cash position alone does not guarantee that programs will reach approval.
What happens next
Definium plans to file its New Drug Application for DT120 ODT in the first half of 2027 and to begin a Phase 3 study for post-traumatic stress disorder in 2027.
Further reading
Explore more Corporate Finance coverage for context on how drug developers fund long clinical programs.
Source note: This article includes information reported by TokenPost.










